Affordable Access

Publisher Website

Screening for aspirin resistance in stable coronary artery patients by three different tests

Thrombosis Research
Publication Date
DOI: 10.1016/j.thromres.2007.04.010
  • Aspirin Resistance
  • Pfa-100
  • Bleeding Time
  • Urinary Thromboxane B2
  • Biology
  • Medicine


Abstract Background Aspirin (ASA) failure to inhibit in vitro platelet function had been termed ASA resistance. The prevalence of this phenomenon as measured with different platelet function tests varies widely among studies. Objectives In this study, we propose to determine the prevalence of ASA non-responsiveness in stable coronary artery patients using three different tests. Patients and methods One hundred ninety-one patients with a stable coronary artery disease and receiving secondary ASA prophylaxis (250 mg/day) were tested. For each patient the ASA-induced platelet inhibition was determined using three different tests: Ivy Bleeding time (BT), collagen/epinephrine closure time (CEPI-CT; PFA-100™, Dade-Behring) and urinary 11-dehydrothromboxane B 2 (uTxB 2) excretion level. The agreement between these tests was evaluated by kappa statistics test. Results The prevalence of biological ASA resistance was 15.7% ( n = 30), 20.4% ( n = 39) and 24.6% ( n = 47) by BT, PFA-100™ and UTxB 2, respectively. Only fourteen patients (7.3%) were non-responders for two tests: 6 (3.1%) BT/ PFA-100™; 1 (0.5%) BT/UTxB 2; 7 (3.7%) PFA-100™/UTxB 2). A poor agreement was found between these three methods and only 3 patients were resistant with all the tests (1.6%). Conclusion The lack of agreement supposed that different types of aspirin resistance exist. Thus, combination of two tests or more could be a primary solution for a better identification of ASA resistant patients. This hypothesis must be confirmed by a large-scale randomized study with clinically well-defined endpoints.

There are no comments yet on this publication. Be the first to share your thoughts.